188 related articles for article (PubMed ID: 20221822)
1. Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments.
Lu J; Gong D; Choong SY; Xu H; Chan YK; Chen X; Fitzpatrick S; Glyn-Jones S; Zhang S; Nakamura T; Ruggiero K; Obolonkin V; Poppitt SD; Phillips AR; Cooper GJ
Diabetologia; 2010 Jun; 53(6):1217-26. PubMed ID: 20221822
[TBL] [Abstract][Full Text] [Related]
2. A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes.
Gong D; Lu J; Chen X; Reddy S; Crossman DJ; Glyn-Jones S; Choong YS; Kennedy J; Barry B; Zhang S; Chan YK; Ruggiero K; Phillips AR; Cooper GJ
Diabetologia; 2008 Sep; 51(9):1741-51. PubMed ID: 18636238
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.
Cooper GJ
Drugs; 2011 Jul; 71(10):1281-320. PubMed ID: 21770477
[TBL] [Abstract][Full Text] [Related]
4. Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment.
Lu J; Pontré B; Pickup S; Choong SY; Li M; Xu H; Gamble GD; Phillips AR; Cowan BR; Young AA; Cooper GJ
Cardiovasc Diabetol; 2013 Jan; 12():28. PubMed ID: 23368770
[TBL] [Abstract][Full Text] [Related]
5. Molecular changes evoked by triethylenetetramine treatment in the extracellular matrix of the heart and aorta in diabetic rats.
Gong D; Lu J; Chen X; Choong SY; Zhang S; Chan YK; Glyn-Jones S; Gamble GD; Phillips AR; Cooper GJ
Mol Pharmacol; 2006 Dec; 70(6):2045-51. PubMed ID: 16973718
[TBL] [Abstract][Full Text] [Related]
6. Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation.
Zhang S; Liu H; Amarsingh GV; Cheung CC; Hogl S; Narayanan U; Zhang L; McHarg S; Xu J; Gong D; Kennedy J; Barry B; Choong YS; Phillips AR; Cooper GJ
Cardiovasc Diabetol; 2014 Jun; 13():100. PubMed ID: 24927960
[TBL] [Abstract][Full Text] [Related]
7. Selective divalent copper chelation for the treatment of diabetes mellitus.
Cooper GJ
Curr Med Chem; 2012; 19(17):2828-60. PubMed ID: 22455587
[TBL] [Abstract][Full Text] [Related]
8. Diabetes-induced alterations in tissue collagen and carboxymethyllysine in rat kidneys: Association with increased collagen-degrading proteinases and amelioration by Cu(II)-selective chelation.
Brings S; Zhang S; Choong YS; Hogl S; Middleditch M; Kamalov M; Brimble MA; Gong D; Cooper GJ
Biochim Biophys Acta; 2015 Aug; 1852(8):1610-8. PubMed ID: 25900786
[TBL] [Abstract][Full Text] [Related]
9. Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats.
Zhang L; Ward ML; Phillips AR; Zhang S; Kennedy J; Barry B; Cannell MB; Cooper GJ
Cardiovasc Diabetol; 2013 Aug; 12():123. PubMed ID: 23981320
[TBL] [Abstract][Full Text] [Related]
10. Quantitative proteomic profiling identifies new renal targets of copper(II)-selective chelation in the reversal of diabetic nephropathy in rats.
Gong D; Chen X; Middleditch M; Huang L; Vazhoor Amarsingh G; Reddy S; Lu J; Zhang S; Ruggiero K; Phillips AR; Cooper GJ
Proteomics; 2009 Sep; 9(18):4309-20. PubMed ID: 19634143
[TBL] [Abstract][Full Text] [Related]
11. Complex formation equilibria of Cu(II) and Zn(II) with triethylenetetramine and its mono- and di-acetyl metabolites.
Nurchi VM; Crisponi G; Crespo-Alonso M; Lachowicz JI; Szewczuk Z; Cooper GJ
Dalton Trans; 2013 May; 42(17):6161-70. PubMed ID: 23202417
[TBL] [Abstract][Full Text] [Related]
12. Low-dose copper infusion into the coronary circulation induces acute heart failure in diabetic rats: New mechanism of heart disease.
Cheung CC; Soon CY; Chuang CL; Phillips AR; Zhang S; Cooper GJ
Biochem Pharmacol; 2015 Sep; 97(1):62-76. PubMed ID: 26208785
[TBL] [Abstract][Full Text] [Related]
13. Regeneration of the heart in diabetes by selective copper chelation.
Cooper GJ; Phillips AR; Choong SY; Leonard BL; Crossman DJ; Brunton DH; Saafi 'L; Dissanayake AM; Cowan BR; Young AA; Occleshaw CJ; Chan YK; Leahy FE; Keogh GF; Gamble GD; Allen GR; Pope AJ; Boyd PD; Poppitt SD; Borg TK; Doughty RN; Baker JR
Diabetes; 2004 Sep; 53(9):2501-8. PubMed ID: 15331567
[TBL] [Abstract][Full Text] [Related]
14. Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients.
Lu J; Chan YK; Gamble GD; Poppitt SD; Othman AA; Cooper GJ
Drug Metab Dispos; 2007 Feb; 35(2):221-7. PubMed ID: 17108057
[TBL] [Abstract][Full Text] [Related]
15. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents.
Cameron NE; Cotter MA
J Clin Invest; 1995 Aug; 96(2):1159-63. PubMed ID: 7635953
[TBL] [Abstract][Full Text] [Related]
16. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.
Cooper GJ; Young AA; Gamble GD; Occleshaw CJ; Dissanayake AM; Cowan BR; Brunton DH; Baker JR; Phillips AR; Frampton CM; Poppitt SD; Doughty RN
Diabetologia; 2009 Apr; 52(4):715-22. PubMed ID: 19172243
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of copper intake: lipid profile, oxidative stress and susceptibility to renal dysfunction.
Galhardi CM; Diniz YS; Faine LA; Rodrigues HG; Burneiko RC; Ribas BO; Novelli EL
Food Chem Toxicol; 2004 Dec; 42(12):2053-60. PubMed ID: 15500942
[TBL] [Abstract][Full Text] [Related]
18. Action of capparis decidua against alloxan-induced oxidative stress and diabetes in rat tissues.
Yadav P; Sarkar S; Bhatnagar D
Pharmacol Res; 1997 Sep; 36(3):221-8. PubMed ID: 9367667
[TBL] [Abstract][Full Text] [Related]
19. Trientine and renin-angiotensin system blockade ameliorate progression of glomerular morphology in hypertensive experimental diabetic nephropathy.
Moya-Olano L; Milne HM; Robinson JM; Hill JV; Frampton CM; Abbott HF; Turner R; Kettle AJ; Endre ZH
Pathol Int; 2011 Nov; 61(11):652-61. PubMed ID: 22029676
[TBL] [Abstract][Full Text] [Related]
20. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
Anjaneyulu M; Chopra K
Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
